Arylamine N-acetyltransferases: Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes

Carston R Wagner, Carl P. Bergstrom, Kristina R. Koning, Patrick E. Hanna

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Two isozymes of arylamine N-acetyltransferases (NATs) catalyze the biotransformation of arylamines to arylamides, and the bioactivation of carcinogenic arylhydroxylamines and arylhydroxamic acids to reactive electrophiles capable of forming a variety of DNA and protein adducts. As part of a project directed toward delineation of the molecular factors responsible for the pronounced differences in the substrate specificity of the isozymes, we have recently reported the expression in Escherichia coli and purification of hamster NAT1 (NAT1 8) as a fusion protein to an antibody- reactive amino terminus FLAG peptide capable of being removed by digestion with enterokinase. Unfortunately, the conditions necessary for the removal of the peptide by enterokinase resulted in incomplete protease digestion and substantial loss of NAT1 activity. Consequently, we have constructed the plasmid pPH8 in which an 11 amino acid thrombin proteolysis site has been inserted between the FLAG peptide and the amino terminus of NAT1. In addition, a plasmid that expresses hamster NAT2 (NAT2 15) was constructed by exchanging the gene sequence for NAT1 with the cloned sequence for NAT2. Both NAT fusion proteins were expressed in JM105 cells. Analysis of catalytically active cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that ~30-fold more soluble NAT2 was expressed than NAT1 in the bacterial cytosol. The fusion proteins were purified to homogeneity by immunoaffinity chromatography, followed by gel filtration to remove high molecular weight contaminants. The FLAG peptide was subsequently removed by treatment with human thrombin, followed by an additional pass over the immunoaffinity column. Unlike the results obtained from proteolysis by enterokinase, the activities of the rNAT1 and rNAT2 were shown to be unaffected by treatment with thrombin. Moreover, the substrate specificities for the recombinant NATs closely matched those observed for NAT1 and NAT2 isolated from hamster liver.

Original languageEnglish (US)
Pages (from-to)245-253
Number of pages9
JournalDrug Metabolism and Disposition
Volume24
Issue number2
StatePublished - Feb 27 1996

Fingerprint

Arylamine N-Acetyltransferase
Enteropeptidase
Substrate Specificity
Cricetinae
Isoenzymes
Thrombin
Escherichia coli
Acetyltransferases
Proteolysis
Digestion
Proteins
Plasmids
DNA Adducts
Biotransformation
Sodium Dodecyl Sulfate
Cytosol
Gel Chromatography
Polyacrylamide Gel Electrophoresis
Peptide Hydrolases
Molecular Weight

Cite this

Arylamine N-acetyltransferases : Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes. / Wagner, Carston R; Bergstrom, Carl P.; Koning, Kristina R.; Hanna, Patrick E.

In: Drug Metabolism and Disposition, Vol. 24, No. 2, 27.02.1996, p. 245-253.

Research output: Contribution to journalArticle

@article{b7a3cae2d3d44662bc8cfca86362d976,
title = "Arylamine N-acetyltransferases: Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes",
abstract = "Two isozymes of arylamine N-acetyltransferases (NATs) catalyze the biotransformation of arylamines to arylamides, and the bioactivation of carcinogenic arylhydroxylamines and arylhydroxamic acids to reactive electrophiles capable of forming a variety of DNA and protein adducts. As part of a project directed toward delineation of the molecular factors responsible for the pronounced differences in the substrate specificity of the isozymes, we have recently reported the expression in Escherichia coli and purification of hamster NAT1 (NAT1 8) as a fusion protein to an antibody- reactive amino terminus FLAG peptide capable of being removed by digestion with enterokinase. Unfortunately, the conditions necessary for the removal of the peptide by enterokinase resulted in incomplete protease digestion and substantial loss of NAT1 activity. Consequently, we have constructed the plasmid pPH8 in which an 11 amino acid thrombin proteolysis site has been inserted between the FLAG peptide and the amino terminus of NAT1. In addition, a plasmid that expresses hamster NAT2 (NAT2 15) was constructed by exchanging the gene sequence for NAT1 with the cloned sequence for NAT2. Both NAT fusion proteins were expressed in JM105 cells. Analysis of catalytically active cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that ~30-fold more soluble NAT2 was expressed than NAT1 in the bacterial cytosol. The fusion proteins were purified to homogeneity by immunoaffinity chromatography, followed by gel filtration to remove high molecular weight contaminants. The FLAG peptide was subsequently removed by treatment with human thrombin, followed by an additional pass over the immunoaffinity column. Unlike the results obtained from proteolysis by enterokinase, the activities of the rNAT1 and rNAT2 were shown to be unaffected by treatment with thrombin. Moreover, the substrate specificities for the recombinant NATs closely matched those observed for NAT1 and NAT2 isolated from hamster liver.",
author = "Wagner, {Carston R} and Bergstrom, {Carl P.} and Koning, {Kristina R.} and Hanna, {Patrick E.}",
year = "1996",
month = "2",
day = "27",
language = "English (US)",
volume = "24",
pages = "245--253",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Arylamine N-acetyltransferases

T2 - Expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes

AU - Wagner, Carston R

AU - Bergstrom, Carl P.

AU - Koning, Kristina R.

AU - Hanna, Patrick E.

PY - 1996/2/27

Y1 - 1996/2/27

N2 - Two isozymes of arylamine N-acetyltransferases (NATs) catalyze the biotransformation of arylamines to arylamides, and the bioactivation of carcinogenic arylhydroxylamines and arylhydroxamic acids to reactive electrophiles capable of forming a variety of DNA and protein adducts. As part of a project directed toward delineation of the molecular factors responsible for the pronounced differences in the substrate specificity of the isozymes, we have recently reported the expression in Escherichia coli and purification of hamster NAT1 (NAT1 8) as a fusion protein to an antibody- reactive amino terminus FLAG peptide capable of being removed by digestion with enterokinase. Unfortunately, the conditions necessary for the removal of the peptide by enterokinase resulted in incomplete protease digestion and substantial loss of NAT1 activity. Consequently, we have constructed the plasmid pPH8 in which an 11 amino acid thrombin proteolysis site has been inserted between the FLAG peptide and the amino terminus of NAT1. In addition, a plasmid that expresses hamster NAT2 (NAT2 15) was constructed by exchanging the gene sequence for NAT1 with the cloned sequence for NAT2. Both NAT fusion proteins were expressed in JM105 cells. Analysis of catalytically active cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that ~30-fold more soluble NAT2 was expressed than NAT1 in the bacterial cytosol. The fusion proteins were purified to homogeneity by immunoaffinity chromatography, followed by gel filtration to remove high molecular weight contaminants. The FLAG peptide was subsequently removed by treatment with human thrombin, followed by an additional pass over the immunoaffinity column. Unlike the results obtained from proteolysis by enterokinase, the activities of the rNAT1 and rNAT2 were shown to be unaffected by treatment with thrombin. Moreover, the substrate specificities for the recombinant NATs closely matched those observed for NAT1 and NAT2 isolated from hamster liver.

AB - Two isozymes of arylamine N-acetyltransferases (NATs) catalyze the biotransformation of arylamines to arylamides, and the bioactivation of carcinogenic arylhydroxylamines and arylhydroxamic acids to reactive electrophiles capable of forming a variety of DNA and protein adducts. As part of a project directed toward delineation of the molecular factors responsible for the pronounced differences in the substrate specificity of the isozymes, we have recently reported the expression in Escherichia coli and purification of hamster NAT1 (NAT1 8) as a fusion protein to an antibody- reactive amino terminus FLAG peptide capable of being removed by digestion with enterokinase. Unfortunately, the conditions necessary for the removal of the peptide by enterokinase resulted in incomplete protease digestion and substantial loss of NAT1 activity. Consequently, we have constructed the plasmid pPH8 in which an 11 amino acid thrombin proteolysis site has been inserted between the FLAG peptide and the amino terminus of NAT1. In addition, a plasmid that expresses hamster NAT2 (NAT2 15) was constructed by exchanging the gene sequence for NAT1 with the cloned sequence for NAT2. Both NAT fusion proteins were expressed in JM105 cells. Analysis of catalytically active cell lysates by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that ~30-fold more soluble NAT2 was expressed than NAT1 in the bacterial cytosol. The fusion proteins were purified to homogeneity by immunoaffinity chromatography, followed by gel filtration to remove high molecular weight contaminants. The FLAG peptide was subsequently removed by treatment with human thrombin, followed by an additional pass over the immunoaffinity column. Unlike the results obtained from proteolysis by enterokinase, the activities of the rNAT1 and rNAT2 were shown to be unaffected by treatment with thrombin. Moreover, the substrate specificities for the recombinant NATs closely matched those observed for NAT1 and NAT2 isolated from hamster liver.

UR - http://www.scopus.com/inward/record.url?scp=0030019667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030019667&partnerID=8YFLogxK

M3 - Article

C2 - 8742238

AN - SCOPUS:0030019667

VL - 24

SP - 245

EP - 253

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 2

ER -